Portfolio company
Apoxis SA
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops therapeutic proteins and small molecules for the treatment of cancer and inflammatory diseases in clinical-stage patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Apexian Pharmaceuticals
This company develops oral small molecule drugs targeting specific proteins to treat patients with cancer and inflammatory bowel diseases.
Apim Therapeutics
This clinical-stage biotechnology company develops peptide drugs targeting cellular stress responses for patients with advanced cancers including ovarian cancer and sarcoma.
APIM Therapeutics AS
This clinical-stage biotechnology company develops peptide drugs targeting cellular stress responses to treat patients with advanced solid tumours and multiple cancers.
Enodia
This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.
Scorpion Therapeutics
This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.
Aptatargets
The company develops aptamer-based therapeutic drugs for patients with acute ischemic stroke and other inflammatory or cardiovascular diseases.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
Apini Therapeutics
This biotechnology company develops small molecule compounds to treat chronic inflammatory diseases for healthcare providers and patients.